CAS 118786-06-4 | CAND-001 : Candoxatril
(World's Largest Pharmaceutical Supplier)

CAS 118786-06-4, also known as atomoxetine, is a medication used in the treatment of attention deficit hyperactivity disorder (ADHD). It belongs to a class of drugs called norepinephrine reuptake inhibitors, which work by increasing the levels of norepinephrine in the brain, a neurotransmitter that plays a role in regulating attention and behavior.

Atomoxetine was approved for use by the United States Food and Drug Administration (FDA) in 2002, and has since become widely prescribed. It is typically taken orally once or twice daily, and is often used as an alternative to stimulant medications such as methylphenidate and amphetamines.

In addition to its primary use in treating ADHD, atomoxetine has also been investigated for its potential use in treating other conditions. For example, some studies have suggested that it may be beneficial in treating depression in patients with ADHD.

Like all medications, atomoxetine can cause side effects. Some common side effects include nausea, dry mouth, and fatigue. In rare cases, it may also cause serious side effects such as increased blood pressure or liver damage.

Despite its potential side effects, atomoxetine has been shown to be an effective treatment for ADHD, helping to improve symptoms such as inattention, hyperactivity, and impulsivity. As such, it is a valuable tool in the management of this neurodevelopmental disorder, and continues to be an important area of research and development in the field of psychiatry.